|Posted on October 3, 2018 at 10:00 PM|
Last Thursday, September 27, 2019 the DEA placed a marijuana-derived drug called Epidiolex (that was granted FDA apprivel 6/25/2018 ), In Schedule V. This is confusing the general public who thinks CBD is all schedule 5 and legal, which it is not. Still considered schedule 1 as of now. Feds versus feds. As I mention in my class for the past 6 months, GW Pharaceuticals will be charging approx $32,500/year for this prescription drug. This is the MAIN reason we do not want cannabis in big pharma's hands. Remember the epipen $$ issue? Same thing!
-Jen C 10/3/2018